Century Therapeutics, Inc. Common Stock
$1.83
-$0.05 (-2.93%)
$1.82Day Range$1.88
Key Statistics
Market Cap
$340.42M
Shares Outstanding
181.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 18, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$1.88
Day High
$1.88
Day Low
$1.82
Volume
202.0K
VWAP
$1.86
Prev Close
$1.88
Transactions
--
Acc. Volume
--
About Century Therapeutics, Inc. Common Stock
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283678 employees25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA215-981-4000IPO Jun 18, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001850119
- Composite FIGI
- BBG00PM8N5W0
- Share Class FIGI
- BBG00PM8N5Y8
- Ticker Root
- IPSC
- SIC Code
- 2836
About Century Therapeutics, Inc. Common Stock (IPSC) Stock
Century Therapeutics, Inc. Common Stock (IPSC) closed the 2026-09-18 session at $1.82, down 2.93% versus the previous close (-0.05). The stock opened at $1.88 and traded between $1.82 and $1.88 during that session. Session trading volume was 202K shares. The volume-weighted average price (VWAP) is $1.86.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Century Therapeutics, Inc. Common Stock has a market capitalization of $340.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. IPSC is listed on the XNAS exchange. The company employs approximately 78 people. Century Therapeutics, Inc. Common Stock is headquartered in PHILADELPHIA, PA. The recorded listing date is 2021-06-18.
On this page you can find market IPSC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.